What Caused HCW Biologics Stock to Jump 102% Overnight?
Stock Surge: HCW Biologics Inc. (HCWB) shares rose 102.72% to $6.73 in after-hours trading after announcing the successful development of second-generation T-cell engagers for solid tumors, specifically targeting pancreatic cancer and glioblastoma.
Promising Preclinical Results: The company's lead candidate showed 100% survival rates in tumor-bearing mice, and non-human primate studies indicated it was well-tolerated without serious side effects, driving investor interest in the stock.
Partnership Strategy: HCW Biologics plans to collaborate with financially strong corporations to enhance development and market entry, aiming to tap into a lucrative market for T-cell engagers, which currently generates billions in annual sales.
Stock Performance Overview: Despite a recent surge, HCWB has experienced significant volatility, with a dramatic decline of approximately 93.4% from its peak price of $49.60 last November, and a current market capitalization of $7.14 million.
Discover Tomorrow's Bullish Stocks Today
Analyst Views on HCWB
About HCWB
About the author
HCW Biologics Inc. (NASDAQ: HCWB) Engages in Virtual Investor "What This Means" Discussion
Company Overview: HCW Biologics Inc. is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to combat age-related diseases and chronic inflammation, utilizing their TRBC drug discovery platform.
Product Candidate: The company's lead product, HCW11-040, is a second-generation immune checkpoint inhibitor that combines pembrolizumab with interleukin-7, interleukin-15, and TGF-β receptor components, showing promise in expanding exhausted T cells without side effects.
Upcoming Presentation: HCW Biologics will present data on HCW11-040 at the 40th annual meeting of the Society for Immunotherapy of Cancer (SITC) on November 8, 2025, highlighting its potential as a novel tetra-specific immunotherapeutic.
Forward-Looking Statements: The company has issued forward-looking statements regarding the efficacy of its pembrolizumab-based TRBC fusion molecules, acknowledging the inherent risks and uncertainties in achieving anticipated results.
HCW Biologics Scientists to Showcase Three Posters at the 40th Annual Society for Immunotherapy of Cancer Meeting
Company Overview: HCW Biologics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies targeting chronic inflammation and related diseases, with a proprietary TRBC platform for creating various immunotherapeutic compounds.
Upcoming Presentations: The company will present three posters at the 40th Annual Meeting of the Society for Immunotherapy of Cancer from November 5 to 9, 2025, showcasing their lead drug candidates and their potential applications in cancer therapy.